introduct
estim
influenza
vaccin
effect
ive
prevent
laboratoryconfirm
influenzarel
hospit
patient
year
old
older
influenza
season
method
conduct
prospect
casecontrol
studi
five
hospit
valencia
spain
studi
subject
consecut
emerg
hospit
predefin
condit
associ
influenzalik
ill
episod
day
admiss
patient
consid
immun
vaccin
day
influenzalik
ill
onset
case
real
time
revers
transcriptas
polymeras
chain
reaction
rtpcr
posit
influenza
control
rtpcr
posit
respiratori
virus
adjust
ive
estim
adjust
odd
ratio
account
indic
bia
comput
adjust
ive
respiratori
syncyti
viru
relat
hospit
result
elig
hospit
patient
influenza
posit
consid
case
posit
respiratori
virus
consid
control
adjust
ive
confid
interv
subgroup
adjust
ive
highrisk
condit
year
age
year
age
highrisk
condit
influenza
vaccin
effect
observ
respiratori
syncyti
viru
relat
hospit
conclus
influenza
vaccin
associ
signific
reduct
risk
confirm
influenza
hospit
irrespect
age
highrisk
condit
yearli
season
influenza
epidem
associ
excess
morbid
mortal
vaccin
influenza
consid
effect
strategi
prevent
influenza
consequ
antigen
drift
influenza
vaccin
produc
everi
year
despit
achiev
vaccin
effect
vari
season
season
low
one
four
influenza
season
due
unpredict
antigen
distanc
vaccin
circul
strain
consequ
evid
influenza
vaccin
effect
difficult
obtain
disput
reapprais
evid
influenza
vaccin
effect
possibl
avail
revers
transcriptas
polymeras
chain
reaction
rtpcr
diagnos
influenza
infect
rtpcr
allow
develop
testneg
approach
measur
influenza
vaccin
effect
testneg
casecontrol
studi
case
rtpcr
posit
influenza
control
neg
influenza
approach
advoc
practic
compar
case
control
use
laboratori
confirm
outcom
variou
author
use
testneg
casecontrol
studi
condit
concurr
circul
appropri
testneg
control
group
patient
test
posit
respiratori
virus
ensur
similar
qualiti
sampl
collect
specif
outcom
use
prospect
casecas
comparison
approach
estim
season
influenza
vaccin
effect
ive
prevent
laboratori
confirm
influenzarel
hospit
adult
influenza
season
perform
prospect
casecontrol
studi
five
hospit
valencia
spain
five
hospit
provid
care
inhabit
year
age
older
influenza
season
defin
week
posit
specimen
influenza
enrol
patient
began
decemb
week
end
march
week
patient
confirm
influenza
rtpcr
test
consid
case
patient
rtpcr
confirm
infect
respiratori
virus
consid
control
influenza
vaccin
offer
free
charg
health
district
inhabit
older
month
age
highrisk
condit
year
old
older
three
vaccin
formul
use
subunit
trival
nonadjuv
vaccin
influvac
abbotsolvay
illinoi
usa
batch
number
offer
subject
less
year
age
virosom
trival
subunit
vaccin
inflex
v
crucel
leiden
netherland
batch
number
offer
subject
year
old
older
tm
adjuv
trival
subunit
vaccin
chiroma
novarti
vaccin
diagnost
massachusett
usa
batch
number
offer
licensur
requir
year
old
older
subunit
trival
nonadjuv
offer
five
health
district
includ
studi
virosom
vaccin
use
two
tm
adjuv
vaccin
use
three
strain
includ
influenza
vaccin
season
like
like
establish
activ
surveil
system
fulltim
field
research
identifi
monday
saturday
patient
hospit
come
emerg
depart
previou
h
patient
whose
indic
admiss
predefin
set
condit
describ
possibl
associ
recent
influenza
infect
invit
particip
patient
exclud
institution
perman
resid
report
egg
allergi
hospit
previou
day
previou
laboratori
confirm
influenza
infect
patient
includ
report
ili
episod
defin
least
one
four
system
symptom
fever
feverish
malais
headach
myalgia
least
one
three
respiratori
symptom
cough
sore
throat
short
breath
sudden
onset
requisit
inclus
less
day
preced
arriv
emerg
depart
ethic
research
committe
centro
superior
de
en
salud
csisp
approv
studi
studi
subject
gave
written
inform
consent
enrol
nasopharyng
pharyng
swab
obtain
includ
patient
sampl
introduc
vial
viral
transport
medium
kept
c
sent
refer
laboratori
four
multiplex
realtim
rtpcrpcr
qualit
amplif
perform
multiplex
influenza
viru
type
influenza
viru
type
b
multiplex
coronaviru
metapneumoviru
bocaviru
multiplex
respiratori
syncyti
viru
rsv
adenoviru
parainfluenza
viru
multiplex
rhinoviru
neg
result
virus
consid
human
ribonucleoprotein
gene
amplif
posit
laboratori
procedur
prevent
pcr
contamin
follow
seri
multiplex
assay
neg
control
without
sampl
nucleic
acid
includ
run
inform
obtain
age
sex
indic
inclus
hospit
date
time
elaps
symptom
onset
swab
presenc
major
underli
medic
condit
longterm
treatment
contact
children
smoke
habit
occup
number
physician
encount
last
three
month
number
hospit
last
year
prescript
antivir
intens
care
unit
admiss
death
hospit
length
stay
function
statu
measur
barthel
index
obtain
studi
subject
year
old
older
social
class
assign
accord
occup
influenza
vaccin
statu
obtain
ask
patient
receiv
current
season
influenza
vaccin
month
vaccin
administ
least
two
week
onset
symptom
addit
vaccin
statu
independ
ascertain
research
blind
patient
characterist
consult
valencia
populationbas
vaccin
inform
system
patient
consid
immun
influenza
vaccin
vaccin
regist
administ
day
date
ili
onset
patient
recal
month
vaccin
administ
administ
two
week
previou
current
ili
episod
onset
inform
relat
administr
season
influenza
vaccin
pandem
vaccin
previou
polysaccharid
plain
pneumococc
vaccin
obtain
vaccin
inform
system
ive
defin
adjust
odd
ratio
adjust
obtain
use
logist
regress
model
use
stepwis
background
select
variabl
criterion
p
remain
model
start
fulli
satur
model
includ
immun
current
season
vaccin
sex
age
year
age
interv
socioeconom
class
number
highrisk
condit
obes
imc
smoke
anteced
number
physician
encount
last
three
month
hospit
last
year
pneumococc
vaccin
antivir
prescript
epidemiolog
week
time
symptom
onset
swab
defin
four
group
ive
estim
case
control
enrol
overal
group
b
case
control
highrisk
condit
regardless
age
c
case
control
year
old
older
case
control
year
old
older
highrisk
condit
valid
estim
comput
ive
rsvrelat
hospit
follow
design
analysi
strategi
follow
influenzarel
hospit
instanc
case
posit
rsv
control
posit
respiratori
virus
includ
influenza
signific
differ
distribut
covari
case
control
estim
use
chisquar
fisher
test
categor
variabl
ttest
kruskalw
test
continu
variabl
p
consid
signific
probabl
analys
perform
stata
statacorp
colleg
station
tx
identifi
elig
patient
compli
inclus
criteria
posit
influenza
consid
case
posit
respiratori
virus
consid
control
fig
swab
perform
day
less
onset
symptom
studi
subject
time
onset
swab
similar
case
control
median
instanc
four
day
p
hospit
rate
associ
respiratori
virus
assess
per
year
old
older
age
group
hospit
rate
associ
respiratori
virus
per
year
old
older
respect
influenzarel
hospit
rate
per
year
old
older
type
number
viru
identifi
rsv
rhinoviru
coronaviru
influenza
b
parainfluenza
viru
mix
infect
human
metaneumoviru
includ
mix
infect
influenza
account
n
respiratori
virus
identifi
influenza
subtyp
identifi
n
influenza
b
n
n
influenza
virus
circul
concurr
rsv
rhinoviru
coronaviru
fig
differ
regard
emerg
admiss
diagnos
case
control
except
heart
failur
case
compar
control
p
tabl
influenza
patient
present
complain
respiratori
condit
tabl
durat
symptom
previou
admiss
evenli
distribut
case
control
p
tabl
differ
percentag
sudden
onset
symptom
malais
myalgia
headach
sore
throat
short
breath
signific
differ
frequenc
fever
influenza
case
p
tabl
compar
control
case
younger
fewer
highrisk
condit
higher
social
class
frequent
smoker
consult
gener
practition
hospit
fewer
occas
tabl
differ
case
control
age
year
barthel
index
score
tabl
restrict
comparison
case
control
presenc
highrisk
condit
differ
remain
signific
age
pneumococc
vaccin
vaccin
previou
current
season
influenza
vaccin
tabl
restrict
year
old
older
age
influenza
vaccin
previou
current
season
influenza
vaccin
remain
signific
differ
case
control
tabl
compar
case
control
immun
influenza
season
vaccin
p
tabl
control
also
often
vaccin
pneumococc
polysaccharid
vaccin
p
season
influenza
p
pandem
p
vaccin
tabl
highrisk
condit
age
taken
account
differ
observ
percentag
case
control
vaccin
pandem
vaccin
tabl
case
control
characterist
vaccin
histori
group
overal
highrisk
condit
year
old
older
highrisk
condit
irrespect
age
differ
p
pneumococc
vaccin
case
vs
control
tabl
differ
observ
case
control
year
old
older
tabl
accord
presenc
highrisk
condit
age
percentag
control
vaccin
vaccin
compar
case
remain
significantli
higher
tabl
current
influenza
season
vaccin
highli
associ
previou
influenzaseason
vaccin
p
age
older
p
adjust
vaccin
effect
prevent
confirm
influenzaassoci
hospit
ci
tabl
subgroup
analysi
highrisk
condit
influenza
vaccin
effect
estim
ci
year
old
older
ci
year
old
older
highrisk
condit
ci
tabl
overal
adjust
rsvassoci
hospit
season
influenza
vaccin
ci
highrisk
condit
ci
year
old
older
ci
year
old
older
highrisk
condit
ci
subject
vaccin
experienc
risk
influenzarel
hospit
two
time
lower
compar
unvaccin
vaccin
prevent
effect
specif
influenza
three
recent
systemat
review
studi
report
influenza
vaccin
efficaci
effect
reach
conclus
evid
ive
prevent
influenza
older
adult
scarc
elus
nonexist
osterholm
et
al
look
studi
publish
januari
februari
outcom
confirm
rtpcr
viral
cultur
estim
base
serolog
outcom
overestim
inactiv
vaccin
efficaci
identifi
two
observ
studi
older
adult
talbot
et
al
studi
three
consecut
season
use
testneg
casecontrol
design
report
pool
adjust
ive
influenzarel
hospit
howev
estim
signific
pool
three
season
recent
castilla
et
al
conclud
ive
prevent
laboratoryconfirm
influenzarel
hospit
adult
year
age
older
influenza
season
influenza
vaccin
effect
depend
close
match
vaccin
strain
circul
strain
influenza
season
hospit
subject
confirm
influenza
immun
season
vaccin
clear
contrast
observ
autumn
pandem
wave
presenc
good
match
circul
vaccin
strain
vaccin
failur
rare
percentag
vaccin
failur
observ
influenza
season
interpret
consid
specimen
collect
europ
show
reduc
activ
vaccin
viru
strain
tri
minim
select
bia
enrol
strategi
base
activ
surveil
system
use
broad
elig
requir
inclus
complet
inclus
enrol
subject
without
previou
knowledg
vaccin
casecontrol
statu
reduc
classif
bia
use
two
independ
sourc
ascertain
vaccin
perform
rtpcr
influenza
diagnosi
casecas
comparison
patient
recal
consid
valid
sourc
influenza
vaccin
statu
limit
recal
bia
uncertainti
date
vaccin
administr
type
vaccin
administ
record
vaccin
reliabl
indic
immun
absenc
record
inform
estim
electron
vaccin
inform
system
sensit
specif
autumn
pandem
wave
data
collect
present
studi
use
captur
recaptur
method
complet
ascertain
electron
vaccin
inform
system
patient
recal
sourc
aim
reduc
classif
bia
consid
studi
subject
vaccin
nonvaccin
ad
inform
provid
sourc
rtpcr
prefer
diagnost
test
influenza
case
statu
misclassif
may
contribut
underestim
ive
falseneg
rtpcr
result
maxim
rtpcr
sensit
includ
patient
onset
symptom
seven
less
day
hospit
pcr
posit
similar
swab
strategi
day
symptom
onset
nondifferenti
misclassif
true
posit
neg
rule
underestim
vaccin
effect
expect
testneg
design
use
minim
casecas
comparison
although
nasopharyng
aspir
consid
best
specimen
detect
influenza
virus
opt
pharyng
throat
nasopharyng
swab
reduc
patient
discomfort
perform
easi
children
nasal
swab
compar
nasopharyng
aspir
detect
major
respiratori
virus
except
rsv
adult
swab
use
studi
respiratori
viru
diseas
ive
obtain
yield
posit
similar
studi
hospit
adult
time
epidem
wave
type
subtyp
identifi
consist
report
spain
surveil
system
swab
reliabl
conveni
altern
obtain
specimen
rtpcr
test
account
day
elaps
symptom
onset
swab
limit
effect
misclassif
true
posit
neg
casecas
analysi
approach
design
assur
compar
control
case
casecas
comparison
approach
case
control
mainli
differ
exposur
correl
associ
outcom
interest
even
plausibl
influenza
respiratori
virus
cocircul
concurr
fig
impact
age
confound
agerel
protect
due
previou
exposur
age
effect
taken
account
adjust
perform
analysi
restrict
year
old
older
vaccin
effect
could
explain
elderli
acquir
protect
due
distant
exposur
similar
strain
consid
preexist
protect
bia
result
debat
first
observ
third
wave
repeat
circul
level
exposur
age
rang
second
agespecif
influenzarel
hospit
rate
popul
two
seven
time
higher
year
age
group
third
seroepidemiolog
studi
describ
persist
protect
antibodi
titer
small
fraction
subject
year
old
older
fourth
cell
epitop
compar
season
respect
conserv
henc
less
depend
age
protect
sever
episod
expect
year
old
older
fifth
vaccin
effect
differ
age
consid
main
weak
studi
number
influenzarel
hospit
although
abl
assess
adjust
ive
larg
group
done
broad
confid
interv
attain
suffici
number
case
provid
robust
ive
estim
viru
strain
vaccin
type
report
ive
estim
low
probabl
bia
current
vaccin
provid
signific
health
benefit
singl
ive
studi
result
difficult
gener
variabl
factor
involv
circul
strain
vaccin
type
composit
match
vaccin
circul
strain
popul
characterist
outcom
measur
limit
generaliz
futur
studi
plan
take
consider
strength
limit
expos
attain
necessari
statist
power
obtain
robust
ive
estim
viru
antigen
subtyp
compar
differ
vaccin
avail
relev
highrisk
group
